Neil E Fleshner, M Scott Lucia, Blair Egerdie, Lorne Aaron, Gregg Eure: Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. In: Lancet (London, England). Band379, Nr.9821, 24. März 2012, S.1103–1111, doi:10.1016/S0140-6736(11)61619-X, PMID 22277570.
A. M. Traish, A. Mulgaonkar, N. Giordano: The dark side of 5α-reductase inhibitors' therapy: sexual dysfunction, high Gleason grade prostate cancer and depression. In: Korean journal of urology. Band 55, Nummer 6, Juni 2014, S. 367–379, Table II, doi:10.4111/kju.2014.55.6.367, PMID 24955220, PMC 4064044 (freier Volltext) (Review).
A.M. Traish, J. Hassani, A.T. Guay, M. Zitzmann, M.L. Hansen: Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. In: The Journal of Sexual Medicine. 8/2011, S. 872–884. doi:10.1111/j.1743-6109.2010.02157.x. PMID 21176115.
A. M. Traish, R. C. Melcangi, M. Bortolato, L. M. Garcia-Segura, M. Zitzmann: Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know? In: Reviews in endocrine & metabolic disorders. Band 16, Nummer 3, September 2015, S. 177–198, doi:10.1007/s11154-015-9319-y, PMID 26296373 (Review).
A. M. Traish: Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It's Time to Sound the Alarm. In: The world journal of men's health. Band 38, Nummer 3, Juli 2020, S. 323–337, doi:10.5534/wjmh.200012, PMID 32202088, PMC 7308241 (freier Volltext) (Review).
Hee Chul Eun u. a.: Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: A randomized, double-blind, placebo-controlled, phase III study. In: Journal of the American Academy of Dermatology, Volume 63, 2010, S. 252–258. doi:10.1016/j.jaad.2009.09.018.
Neil E Fleshner, M Scott Lucia, Blair Egerdie, Lorne Aaron, Gregg Eure: Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. In: Lancet (London, England). Band379, Nr.9821, 24. März 2012, S.1103–1111, doi:10.1016/S0140-6736(11)61619-X, PMID 22277570.
A. M. Traish, A. Mulgaonkar, N. Giordano: The dark side of 5α-reductase inhibitors' therapy: sexual dysfunction, high Gleason grade prostate cancer and depression. In: Korean journal of urology. Band 55, Nummer 6, Juni 2014, S. 367–379, Table II, doi:10.4111/kju.2014.55.6.367, PMID 24955220, PMC 4064044 (freier Volltext) (Review).
A.M. Traish, J. Hassani, A.T. Guay, M. Zitzmann, M.L. Hansen: Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. In: The Journal of Sexual Medicine. 8/2011, S. 872–884. doi:10.1111/j.1743-6109.2010.02157.x. PMID 21176115.
A. M. Traish, R. C. Melcangi, M. Bortolato, L. M. Garcia-Segura, M. Zitzmann: Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know? In: Reviews in endocrine & metabolic disorders. Band 16, Nummer 3, September 2015, S. 177–198, doi:10.1007/s11154-015-9319-y, PMID 26296373 (Review).
A. M. Traish: Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It's Time to Sound the Alarm. In: The world journal of men's health. Band 38, Nummer 3, Juli 2020, S. 323–337, doi:10.5534/wjmh.200012, PMID 32202088, PMC 7308241 (freier Volltext) (Review).